Intech Biopharm Corporation (6461.TWO)
- Previous Close
17.95 - Open
18.00 - Bid 17.95 x --
- Ask 18.10 x --
- Day's Range
17.90 - 18.00 - 52 Week Range
16.50 - 34.60 - Volume
10,069 - Avg. Volume
68,471 - Market Cap (intraday)
2.476B - Beta (5Y Monthly) -0.01
- PE Ratio (TTM)
-- - EPS (TTM)
-2.68 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. It owns iLEF (inhaled low ethanol formulation), a metered dose inhaler platform for treating asthma and COPD; and dry powder inhaler, a product comprises of blisters and capsules. The company offers its products under the SYN006, SYN010, SYN007, Synflutide, Duasma, Synvent, and SYN011 names. Intech Biopharm Corporation was founded in 2010 and is headquartered in Taipei, Taiwan.
www.intechbiopharm.comRecent News: 6461.TWO
View MorePerformance Overview: 6461.TWO
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is TSEC CAPITALIZATION WEIGHTED ST (^TWII) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 6461.TWO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 6461.TWO
View MoreValuation Measures
Market Cap
2.48B
Enterprise Value
3.65B
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
61.95
Price/Book (mrq)
3.04
Enterprise Value/Revenue
91.85
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-8.72%
Return on Equity (ttm)
-37.15%
Revenue (ttm)
39.78M
Net Income Avi to Common (ttm)
-368.21M
Diluted EPS (ttm)
-2.68
Balance Sheet and Cash Flow
Total Cash (mrq)
258.65M
Total Debt/Equity (mrq)
176.41%
Levered Free Cash Flow (ttm)
-206.2M